Tamarack Advisers’s BioMarin Pharmaceuticals BMRN Stock Holding History

Tamarack Advisers’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-75,000	Closed	-$6.5M	–	25
2023 Q2	$6.5M	Buy	+75,000	New	+$7.06M	2.01%	9
2022 Q4	–	Sell	-71,000	Closed	-$6.02M	–	38
2022 Q3	$6.02M	Buy	71,000 +41,000	+137%	+$3.65M	3.53%	10
2022 Q2	$2.49M	Buy	+30,000	New	+$2.39M	1.44%	21
2022 Q1	–	Sell	-90,000	Closed	-$7.95M	–	48
2021 Q4	$7.95M	Buy	+90,000	New	+$7.43M	3.27%	11

Other funds holding BMRN

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Tamarack Advisers's BMRN Position: Q3 2023 in Review

Tamarack Advisers sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2023, closing a stake of 75,000 shares — an estimated $6.5M sold.

Tamarack Advisers first reported a position in BMRN in Q4 2021 and held it in 4 quarters. The position peaked at $7.95M in Q4 2021. 519 funds tracked by Wall St. Rank hold BMRN as of Q3 2023.

Tamarack Advisers reported no remaining BioMarin Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Tamarack Advisers sold 75,000 BioMarin Pharmaceuticals shares in Q3 2023, an estimated $6.5M.
Tamarack Advisers first reported a position in BioMarin Pharmaceuticals in Q4 2021 and held it in 4 quarters.
Tamarack Advisers's BioMarin Pharmaceuticals position peaked at $7.95M in Q4 2021.
519 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2023.

Based on Tamarack Advisers's 13F filing for Q3 2023, filed 16 Nov 2023.